Amryt Pharma plc (LON:AMYT – Get Free Report)’s share price fell 11.7% on Friday . The company traded as low as GBX 143 ($1.80) and last traded at GBX 143 ($1.80). 90,726 shares were traded during mid-day trading, a decline of 81% from the average session volume of 469,552 shares. The stock had previously closed at GBX 162 ($2.04).
Amryt Pharma Stock Performance
The stock has a market cap of £457.11 million and a PE ratio of -4.33. The company has a debt-to-equity ratio of 66.05, a current ratio of 1.80 and a quick ratio of 1.14. The stock has a 50-day simple moving average of GBX 143 and a 200-day simple moving average of GBX 143.
About Amryt Pharma
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy.
Recommended Stories
- Five stocks we like better than Amryt Pharma
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- 3 Best Fintech Stocks for a Portfolio Boost
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
